$1,440,000 of JOHNSON & JOHNSON SERVICES INC lobbying was just disclosed, from Q2 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"S.4784/H.R. 8800 National Defense Authorization Act (NDAA), regarding provision prohibiting Department of Defense (DOD) contracted companies from engaging in stock buybacks and issuing shareholder dividends absent a waiver from the Secretary - H.R. 1539, Medical Device Electronic Labeling Act, regarding all provisions - H.R. 929/S. 266, the Dr. Lorna Breen Health Care Provider Protection Reauthorization Act, regarding all provisions - H.R. 946 ORPHAN Cures Act, regarding all provisions - S.864, HELP Copays Act, regarding all provisions - H.R. 2214, Delinking Revenue from Unfair Gouging (DRUG) Act, regarding all provisions - H.R. 1492/S. 832, Ensuring Pathways to Innovative Cures (EPIC) Act - S. 1954/ H.R. 5526 Biosimilar Red Tape Elimination Act, regarding all provisions - H.R.2527, Early Detection of Vision Impairments for Children Act of 2025, regarding all provisions - PL117-169 The Inflation Reduction Act, regarding all provisions related to drug pricing and implementation - H.R.5343/S. 1717, the Ensuring Patient Access to Critical Breakthrough Products Act of 2025, regarding all provisions - H.R.4282, Contact Lens Prescription Verification Modernization Act, regarding all provisions - H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act, regarding all provisions - S.1399 / H.R. 6197, the Health Tech Investment Act, regarding all provisions - H.R. 3521, the Clinical Trial Modernization Act, regarding all provisions - H.R. 3006 / S.1776, the Medicare Beneficiary Co-Pay Fairness Act, regarding all provisions - H.R. 3514, the Improving Seniors Timely Access to Care Act of 2025, regarding all provisions - H.R. 6549, the VA Contracting and Procurement Act, regarding all provisions - H.R. 5509 / S. 2903, Safe Step Act, regarding all provisions - H.R. 5256, 340B ACCESS Act, regarding all provisions - H.R. 7391, Community Health Center Drug Pricing Protection Act, regarding all provisions Issues related to - direct to consumer advertising - clinical trial modernization - biosimilars - cardiovascular health - 340B and 340B Rebate Pilot - Heart Recovery Awareness Day & H.Res. 1301, designating February 20th Heart Recovery Awareness Day - obesity treatments - MFN - Foreign Reference Pricing - CMS Outpatient Prospective Payment System rule - peripheral artery disease (PAD) - PBM and Insurer Reforms - Issues related to stroke care - S. 1040, Drug Competition Enhancement Act, regarding all provisions - S. 1041, Affordable Prescriptions for Patients Act of 2025, regarding all provisions - S. 1097, Interagency Patent Coordination and Improvement Act of 2025, regarding all provisions - H.R. 3269/S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act, regarding all provisions - S.2658, Medication Affordability and Patent Integrity Act Issues related to: - intellectual property, including amending the Federal Trade Commission Act to prohibit product hopping - patent thickets - patent fees Issues related to - H.R. 1109, the Litigation Transparency Act of 2025, and transparency in domestic third-party litigation funding - H.R.2675, Protecting Our Courts from Foreign Manipulation Act, and transparency in foreign third-party litigation funding - H.R. 2483, "SUPPORT for Patients and Communities Reauthorization Act of 2025", regarding all provisions. H.R.8413, the SECURE Data Act, regarding all provisions Issues related to - artificial intelligence - data privacy - cybersecurity - robotics Issues related to - OECD proposals on global tax & implementation and/or related Presidential executive orders - corporate tax provisions in OBBB and the corporate alternative minimum tax - use of excess pension funds Issues related to: - Veterans Administration and Veterans Health Administration procurement and contracting processes for medical technology - VA Program - military/veterans affairs health workforce and talent workforce - Issues related to USMCA review and renegotiation"
You can find more data on corporate lobbying on Quiver Quantitative.
JNJ Congressional Stock Trading
Members of Congress have traded $JNJ stock 9 times in the past 6 months. Of those trades, 2 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $JNJ stock by members of Congress over the last 6 months:
- REPRESENTATIVE THOMAS H. KEAN, JR. has traded it 4 times. They made 0 purchases and 4 sales worth up to $95,000 on 06/29, 06/02, 03/26, 01/23.
- REPRESENTATIVE LLOYD DOGGETT has traded it 2 times. They made 2 purchases worth up to $30,000 on 06/09, 03/10 and 0 sales.
- REPRESENTATIVE RICHARD MCCORMICK has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 03/19.
- SENATOR JOHN BOOZMAN sold up to $15,000 on 03/19.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
JNJ Insider Trading Activity
JNJ insiders have traded $JNJ stock on the open market 18 times in the past 6 months. Of those trades, 0 have been purchases and 18 have been sales.
Here’s a breakdown of recent trading of $JNJ stock by insiders over the last 6 months:
- JOAQUIN DUATO (CEO and Chairman of the Board) has made 0 purchases and 2 sales selling 100,000 shares for an estimated $22,122,893.
- JOSEPH J WOLK (Exec VP, CFO) has made 0 purchases and 4 sales selling 89,654 shares for an estimated $21,767,826.
- JAMES D. SWANSON (EVP, CIO) has made 0 purchases and 3 sales selling 62,080 shares for an estimated $15,109,758.
- JOHN C REED (EVP, Innovative Medicine, R&D) has made 0 purchases and 3 sales selling 53,931 shares for an estimated $13,105,233.
- TIMOTHY SCHMID (EVP, WW Chair, MedTech) has made 0 purchases and 3 sales selling 23,945 shares for an estimated $5,852,268.
- KATHRYN E WENGEL (EVP, Chief TO and Risk Officer) sold 10,000 shares for an estimated $2,411,500
- VANESSA BROADHURST (EVP, Global Corp Affairs) sold 6,197 shares for an estimated $1,508,287
- ROBERT J DECKER (VP Corporate Controller) sold 4,075 shares for an estimated $1,010,070
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
JNJ Hedge Fund Activity
We have seen 1,843 institutional investors add shares of JNJ stock to their portfolio, and 2,063 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HIGHTOWER ADVISORS, LLC added 6,535,453 shares (+165.5%) to their portfolio in Q1 2026, for an estimated $1,594,160,373
- FMR LLC added 5,995,157 shares (+31.9%) to their portfolio in Q1 2026, for an estimated $1,462,368,671
- CAPITAL RESEARCH GLOBAL INVESTORS added 5,870,178 shares (+204.5%) to their portfolio in Q1 2026, for an estimated $1,431,883,168
- CAPITAL INTERNATIONAL INVESTORS removed 4,853,668 shares (-65.0%) from their portfolio in Q1 2026, for an estimated $1,183,930,966
- BLACKROCK, INC. added 4,604,387 shares (+2.2%) to their portfolio in Q1 2026, for an estimated $1,123,125,098
- DIAMANT ASSET MANAGEMENT, INC. added 4,454,778 shares (+24436.5%) to their portfolio in Q1 2026, for an estimated $1,086,631,723
- PRICE T ROWE ASSOCIATES INC /MD/ added 4,067,247 shares (+32.7%) to their portfolio in Q1 2026, for an estimated $992,103,224
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
JNJ Analyst Ratings
Wall Street analysts have issued reports on $JNJ in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Morgan Stanley issued a "Overweight" rating on 01/28/2026
To track analyst ratings and price targets for JNJ, check out Quiver Quantitative's $JNJ forecast page.
JNJ Price Targets
Multiple analysts have issued price targets for $JNJ recently. We have seen 12 analysts offer price targets for $JNJ in the last 6 months, with a median target of $259.0.
Here are some recent targets:
- Joanne Wuensch from Citigroup set a target price of $298.0 on 07/08/2026
- Terence Flynn from Morgan Stanley set a target price of $284.0 on 07/08/2026
- Vamil Divan from Guggenheim set a target price of $270.0 on 06/26/2026
- David Risinger from Leerink Partners set a target price of $265.0 on 05/13/2026
- Larry Biegelsen from Wells Fargo set a target price of $263.0 on 04/15/2026
- Rick Wise from Stifel set a target price of $250.0 on 04/15/2026
- Matt Miksic from Barclays set a target price of $255.0 on 04/15/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
